Group 1: Company Performance and Financials - The revenue from Jiangsu Chuangying's implant代理 in 2022 was approximately ¥30,695,664.35, accounting for over 7% of total revenue [2] - The sales revenue of oral repair membranes in 2022 was ¥20,717.87 million [4] - The decline in performance in Q4 2022 was primarily due to the impact of domestic COVID-19 on the oral implant sector [2] Group 2: Product Development and Sales - The active biological bone product has been developed over 14 years and is the first of its kind to receive certification in China, which is expected to open up growth opportunities for the company [6] - The sales of active biological bone have commenced, but actual sales figures will depend on future market promotion effectiveness [6] - The company is actively expanding its sales layout for active biological bone across various provinces [5] Group 3: Market Strategy and Competition - The company is monitoring the centralized procurement policies for oral-related products and will respond proactively [1] - The company has successfully participated in centralized procurement in six provinces for its absorbable hard brain (spinal) membrane, maintaining a record of winning all bids [6] - The company holds a strong advantage in the oral channel and is focused on leveraging past successful experiences to maintain its market position [6]

Revenue and Financial Performance - The company's operating revenue for 2022 was ¥433,224,730.58, an increase of 8.26% compared to ¥400,175,251.94 in 2021[28]. - The net profit attributable to shareholders for 2022 was ¥185,436,805.06, reflecting a growth of 10.02% from ¥168,552,584.39 in 2021[28]. - The net profit after deducting non-recurring gains and losses was ¥172,608,159.41, up 7.29% from ¥160,878,004.21 in 2021[28]. - The net cash flow from operating activities increased by 13.06% to ¥187,838,040.27 in 2022 from ¥166,134,014.20 in 2021[28]. - Basic earnings per share rose by 36.17% to ¥1.28 in 2022, compared to ¥0.94 in 2021[28]. - Total assets at the end of 2022 reached ¥986,904,775.50, a 6.24% increase from ¥928,920,991.12 at the end of 2021[28]. - The net assets attributable to shareholders increased by 10.17% to ¥865,107,791.65 at the end of 2022 from ¥785,270,986.59 at the end of 2021[28]. - The company achieved a net profit of 185.44 million yuan in 2022, representing a year-on-year growth of 10.02%[49]. - Total revenue for 2022 reached 433.22 million yuan, an increase of 8.26% compared to the previous year[50]. Product Development and Market Position - The main revenue sources for the company are the oral repair membrane and absorbable dura (spinal) membrane patches, both of which have experienced rapid growth in recent years[5]. - The company is focused on regenerative medicine, aiming to develop innovative products to meet clinical needs[36]. - The company’s R&D efforts are aimed at developing new products, although the process is lengthy and involves significant investment[7]. - The company has successfully registered new products including "self-etching adhesive" and "active biological bone," expanding its product offerings[45]. - The company is currently conducting clinical trials for several key projects, including light-cured composite resin and calcium silicate bioceramic bone repair materials[79]. - The company is in the process of launching new products, including a breast patch for reconstruction and a uterine cavity repair membrane[79]. - The company is actively developing new products and technologies, with a focus on enhancing the efficacy of its active biological bone and skin repair membrane[110]. Risk Management and Challenges - The company emphasizes the importance of enhancing management capabilities and market expansion to mitigate potential risks from external changes[5]. - The company is focused on addressing risks related to product concentration and external environmental changes, which could affect future growth[5]. - Regulatory changes and external environment shifts, including centralized procurement policies, present ongoing challenges for maintaining market competitiveness[105]. - The company faces risks due to a concentrated product portfolio, with a focus on regenerative medicine and ongoing development of new products like active biological bone and second-generation dura membranes[104]. - Product quality is critical, as any issues could adversely affect both health outcomes and the company's operations[106]. Governance and Management - The company has established a governance structure that ensures compliance with relevant laws and regulations, enhancing operational transparency and risk management[113]. - The board of directors consists of 9 members, including 3 independent directors, ensuring compliance with legal and regulatory requirements[115]. - The company has maintained independence from its controlling shareholder in terms of assets, personnel, finance, and operations, achieving a "five independence" standard[117]. - The company has a strong management team with members holding advanced degrees and extensive experience in the biotechnology and pharmaceutical sectors[126]. - The company has appointed several independent directors with significant experience in finance and management to strengthen its governance[124]. Shareholder Engagement and Profit Distribution - The profit distribution plan approved by the board is a cash dividend of 6.00 RMB per 10 shares (including tax), with no bonus shares issued[7]. - The company aims to distribute at least 20% of the annual distributable profit as cash dividends, increasing to 10% if there are significant investment plans or cash expenditures[145]. - The company has maintained a stable profit distribution policy, with adjustments requiring thorough research and approval from the board and shareholders[150]. - The board of directors will consider shareholder feedback, especially from minority shareholders, when proposing cash dividend plans[148]. - The company distributed a cash dividend of RMB 105.6 million to shareholders, with a distribution of RMB 8.80 per 10 shares[166]. Market Expansion and Sales Strategy - The company has successfully participated in volume-based procurement in six provinces, including Jiangsu and Shandong, without significant pressure on performance, although future expansions of procurement may impact growth[5]. - The company is focusing on expanding its market presence and product applications, particularly in the fields of oral repair and neurosurgery[110]. - The company actively participated in around 750 academic activities to enhance market presence and brand recognition[52]. - The company has over 1,100 distributors nationwide, ensuring a broad marketing network and strong brand recognition in the market[62]. - The company is exploring potential mergers and acquisitions to bolster its market position and expand its product offerings[110]. Quality Management and Compliance - The company has established a comprehensive quality management system, achieving ISO 13485 and ISO 9001 certifications[64]. - The quality management system maintained a 100% pass rate for product inspections, ensuring stable and effective quality management throughout the reporting period[57]. - The company has implemented a supplier evaluation management system, conducting annual assessments to control product quality from the source[171]. - The company has established a monitoring group for adverse events related to product quality, ensuring rapid response and consumer protection[170]. - The internal control system has been strengthened to ensure compliance with laws and regulations, enhancing risk management and operational efficiency[155]. Employee Development and Welfare - The total number of employees at the end of the reporting period is 376, with 163 in production, 105 in sales, 61 in technical roles, 7 in finance, and 40 in administration[140]. - The company has established a comprehensive employee welfare system, providing nearly 20 types of benefits[168]. - The company has conducted training programs to enhance employee skills and support business innovation[168]. - The company emphasizes continuous and stable profit distribution policies, prioritizing cash dividends over stock dividends[144]. Environmental Responsibility - The company has implemented various environmental protection measures, including the installation of pollution control equipment and the use of natural gas boilers[162]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[163]. - Environmental protection measures include the installation of various eco-friendly equipment, ensuring compliance with local environmental regulations[171].

2022 年度网上业绩说明会 证券代码：300653 证券简称：正海生物 公告编号：2023-024 欢迎广大投资者积极参与！ 特此公告。 烟台正海生物科技股份有限公司 关于举办 2022 年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 烟台正海生物科技股份有限公司（以下简称"公司"）2022 年年度报告全文 及摘要已于 2023 年 4 月 11 日刊登于中国证监会指定信息披露网站巨潮资讯网 （http://www.cninfo.com.cn）。为便于投资者能够进一步了解公司的生产经营情况， 公司将于 2023 年 4 月 12 日（周三）15:00-17:00 在机会宝和中国证券报·中证 网举办 2022 年度网上业绩说明会。本次网上业绩说明会将采用网络远程的方式 举行，投资者可登录机会宝（https://n.jhbshow.com/live-text/2124749310 或扫描下 方二维码）和中证路演中心（https://www.cs.com.cn/roadshow/yjsmh/300653_2022/） 参与本年度业绩说明会 ...

证券代码：300653 证券简称：正海生物 烟台正海生物科技股份有限公司 投资者关系活动记录表 | --- | --- | --- | --- | --- | |-------------------------|----------------------------------------------|-----------------------------------------------------------------------|----------------------------------------------------------------------------------|---------| | 投资者关系 活动类别 | þ \n□ | 特定对象调研 □媒体采访 □分析师会议 \n新闻发布会 □业绩说明会 □路演活动 | 编号： | 2017001 | | | □ 现场参观 □其他： | | 海通证券贺文斌，德传医疗姜广策，兴业证券张佳博，东吴证券许汪洋，华创 | | | 参与单位名称 及人员姓名 | | | 证券宋凯，雷钧资产李武跃，硕估投资苏志敏，首善财富徐迅捷 | ...

证券代码：300653 证券简称：正海生物 烟台正海生物科技股份有限公司 投资者关系活动记录表 编号：2020002 | --- | --- | --- | --- | |-----------------|----------------------------------------------------------|------------------------------------|-------| | | | | | | | √ | 特定对象调研 □媒体采访 □分析师会议 | | | 投资者关系 | | □新闻发布会 □业绩说明会 □路演活动 | | | 活动类别 | □ 现场参观 □其他： | | | | 参与单位 | 上海中润投资 唐煜 | | | | 名称及人员 姓名 | 中信证券 陈旺 | | | | 时 间 | 2020 年 5 月 21 | 日 下午 2:30-3:30 | | | 地 点 | | 烟台正海生物科技股份有限公司会议室 | | | 上市公司 | | | | | 接待人员 | | 副总经理、董事会秘书：陆美娇女士 | | | 姓名 | | | | | | | 投资者关系 ...

证券代码：300653 证券简称：正海生物 烟台正海生物科技股份有限公司 投资者关系活动记录表 编号：2020001 | --- | --- | --- | --- | |-----------------|--------------------------|----------------------------------------|------------------------------------------------------| | | √ | 特定对象调研 □媒体采访 □分析师会议 | | | 投资者关系 | | □新闻发布会 □业绩说明会 □路演活动 | | | 活动类别 | □ 现场参观 □其他： | | | | 参与单位 | | 上海恒复投资—周小钢，长城证券—穆云吉， | | | 名称及人员 姓名 | | | 个人投资者夏菊、姜荣光、赵连平、李君兰、李发亮、周洁 | | 时 间 | 2020 年 5 月 20 | 日 下午 3:00—4:00 | | | 地 点 | | 烟台正海生物科技股份有限公司会议室 | | | | 董事长：王涛先生 | | | | 上市公司 | 董事、总 ...

证券代码：300653 证券简称：正海生物 烟台正海生物科技股份有限公司 投资者关系活动记录表 编号：2020004 | --- | --- | --- | --- | |-----------------|-------------------------|----------------------------------------------------------|-------| | | | | | | | √ | 特定对象调研 □媒体采访 □分析师会议 | | | 投资者关系 | □ | 新闻发布会 □业绩说明会 □路演活动 | | | 活动类别 | □ 现场参观 □其他： | | | | 参与单位 | | 平安证券 叶寅、民生证券 盛丽华、大成基金 李林益 | | | 名称及人员 姓名 | | 建信基金 王丽媛、前海开源基金 詹世乾 | | | 时 间 | 2020 年 6 月 10 | 日 下午 3:00-4:30 | | | | | | | | 地 点 | | 烟台正海生物科技股份有限公司会议室 | | | 上市公司 | 董事长：王涛先生 | | | | 接待人员 姓名 | | 副总经理、 ...

证券代码：300653 证券简称：正海生物 烟台正海生物科技股份有限公司 投资者关系活动记录表 编号：2020005 | --- | --- | --- | --- | |-------------------|-----------------------------|-------------------------------------------------|------------------| | | √ | 特定对象调研 □媒体采访 □分析师会议 | | | 投资者关系 | □ | 新闻发布会 □业绩说明会 □路演活动 | | | 活动类别 | □ 现场参观 □其他 | | | | | | 平安证券 韩盟盟，信达证券 张雪，煜德基金 孟晓璐 | | | 参与单位 | | 中融基金 杜伟，长盛基金 张伟光，财信证券 李侃 | | | 名称及人员 姓名 | 重庆穿石投资 蔡生俭、王先俊 | | | | | | 个人投资者 项光隆、姜荣光、赵连平、许更生 | | | 时 间 | 2020 年 8 月 26 | 日 下午 3:10-4:30 | 公司股东大会之后 | | 地 点 | | 烟台正海生物科 ...

Group 1: Product Applications and Regulatory Status - The main applications of active biological bone include treatment for bone defects, bone necrosis, delayed healing, and non-union, as per the approved scope by the drug regulatory authority [2] - Active biological bone is currently in the technical approval stage, with the company actively supplementing necessary data and information [2] - The impact of volume-based procurement on the company's existing products is not yet clear, as current products are high-value medical consumables [2] Group 2: Market Performance and Revenue - In 2019, the company achieved revenue of 136.76 million CNY from oral repair membranes, representing a year-on-year growth of 30.11%, with approximately 50% of this revenue coming from private dental channels [3] - The company aims to continuously disclose information related to private channels in future reports as these channels are growing faster than public ones [3] Group 3: Competitive Landscape and Industry Position - The industry has high entry barriers, and new entrants face a long market development cycle, with competition primarily among established companies with technological advantages [3] - The company is focused on upgrading its products, such as the new generation of biological hard brain (spinal) membrane patches, to maintain its competitive edge in the neurosurgery field [3] Group 4: Talent Management and Incentives - The company emphasizes talent development and management, considering equity incentive plans based on various developmental needs [4] - The company ensures compliance with information disclosure regulations, maintaining the accuracy and timeliness of disclosed information [4]

证券代码：300653 证券简称：正海生物 烟台正海生物科技股份有限公司 投资者关系活动记录表 编号：2017002 | --- | --- | --- | --- | |--------------------------|----------------------------------------------------------|-----------------------------------------------------------------------|------------------------------------------------------------------| | 投资者关系 \n活动类别 | þ \n□ \n□ 现场参观 □其他： | 特定对象调研 □媒体采访 □分析师会议 \n新闻发布会 □业绩说明会 □路演活动 | | | 参与单位 名称及人员 姓名 | | 民生证券肖汉山、袁中平，财通基金钱正昊 | | | 时 间 | 2017 年 11 月 10 | 日 9:30—10:30 | | | 地 点 | | 烟台正海生物科技股份有限公司会议室 | ...